Outcomes Research Should Come After Approval, FDA’s McClellan Says
Executive Summary
The appropriate timing for outcomes research is after a product is approved for commercial marketing, FDA Commissioner McClellan told a recent conference on outcomes research sponsored by Merck and AARP
You may also be interested in...
AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”
Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15
AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”
Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15
Sen. Baucus Urges More Comparative Research At Vioxx Hearing
The Vioxx withdrawal demonstrates the need for more comparative research on drugs, Sen. Max Baucus (D-N.M.) suggested in his questioning of witnesses at the Senate Finance Committee's hearing on Merck's withdrawal of the COX-2 inhibitor